Company

Bone Biologics Corp

Headquarters: Burlington, MA, United States

Employees: 2

CEO: Mr. Jeffrey Frelick

OTC: BBLG +21.05%

Market Cap

$2.7 Million

USD as of Jan. 1, 2024

Market Cap History

Bone Biologics Corp market capitalization over time

Evolution of Bone Biologics Corp market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Bone Biologics Corp

Detailed Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Bone Biologics Corp has the following listings and related stock indices.


Stock: OTC: BBLG wb_incandescent

Details

Headquarters:

2 Burlington Woods Drive

Suite 100

Burlington, MA 01803

United States

Phone: 781 552 4452